证券代码：603566 证券简称：普莱柯 公告编号：2025-024 普莱柯生物工程股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/10 | － | 2025/6/11 | 2025/6/11 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 差异化分红送转方案： （1）根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定, 上市公司回购专用账户中的股份，不享有利润分配的权利。根据公司 2024 年年度股东大会 决议， ...

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 差异化分红事项的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 差异化分红事项的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 差异化分红事项的 法律意见 德恒 01G20240892-02 号 致：普莱柯生物工程股份有限公司 北京德恒律师事务所（以下简称"本所"）接受普莱柯生物工程股份有限公 司（以下简称"普莱柯"或"公司"）的委托，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等有 关法律法规、规范性文件和《普莱柯生物工程股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责 精神，就公司 2024 年度利润分配所涉及的差异化分红（以下简称"本次差异化 分红"）相关事项出具本法律意见。 为出具本法律意见，本所律师查 ...

Investment Rating - The report maintains a "Recommendation" rating for the animal health industry, expecting it to outperform the benchmark index by over 5% in the next 3-6 months [79]. Core Insights - The report highlights significant growth in vaccine approvals for circular, pseudorabies, and diarrhea vaccines, with notable year-on-year increases [7][8]. - The animal drug raw material market shows a continued strong performance in macrolide products, with price indices reflecting a structural differentiation among various products [52][53]. - The overall demand for animal health products is expected to recover, driven by improved profitability in the breeding sector and the introduction of new products [68][69]. Summary by Sections Vaccine Approvals - In April, major vaccine varieties for pigs showed substantial year-on-year growth, with circular vaccine up by 71.2%, pseudorabies vaccine by 73.3%, and diarrhea vaccine by 220% [7][8]. - Cumulative data from January to April indicates most vaccine types experienced significant growth, particularly in pig vaccines, with circular vaccine up by 52.3% and pseudorabies vaccine by 48.2% [8][9]. Raw Material Prices - As of the end of April, the Veterinary Pharmaceutical Index (VPI) was 69.2, reflecting a 5.6% increase from the previous month and a 13.4% increase year-on-year [52][53]. - Prices for macrolide products such as Tylosin, Tylvalosin, and Tilmicosin have shown strong performance, with increases of 10.1%, 17.6%, and 15.4% respectively compared to the end of March [53][54]. Market Outlook - The report anticipates a stable upward trend in the demand for animal health products, supported by a robust breeding sector and ongoing product innovation [68][69]. - The competitive landscape is expected to lead to a dual recovery in performance and valuation for the sector, with a focus on larger companies that can leverage their financial strength and product diversity [69][70]. Investment Recommendations - The report suggests focusing on companies such as Reap Bio, Kexin Bio, and others, which are well-positioned to benefit from the anticipated market recovery [68][70].

Investment Rating - Industry Rating: Recommended [3] Core Views - The planting industry is seeing significant progress with summer grain wheat harvest, reaching over 30% completion as of May 30, with favorable weather conditions expected to enhance soil moisture and facilitate mechanized sowing [10][11] - The commercialization of genetically modified crops is anticipated to accelerate, aiming to improve yield and self-sufficiency in key varieties, supported by government initiatives to protect new plant varieties [10] - In the pig farming sector, the average price of live pigs is showing a slight increase, with a current price of 14.39 CNY/kg, reflecting a week-on-week rise of 0.36% [11][60] - The supply of breeding sows has slightly decreased, with a total of 40.38 million heads reported, while slaughtering volumes have increased significantly year-on-year [11][60] Summary by Sections Planting Industry - As of May 30, 1.29 million acres of summer wheat have been harvested, with regions like Hubei and Sichuan completing their harvests [10] - The Ministry of Agriculture emphasizes the importance of mechanization to enhance yield and efficiency in sowing [10] - Recommended stocks include Beidahuang and Suqian Agricultural Development for planting, and leading seed companies like Longping High-Tech and Dabeinong for seed production [10] Pig Farming - The average price of external three-way cross pigs is 14.39 CNY/kg, with a slight increase from the previous week [11] - The number of breeding sows has decreased slightly, while slaughtering volumes have increased by 20% year-on-year [11] - Recommended stocks in the breeding sector include Dekang Agriculture, Jinke Smart Agriculture, and Muyuan Foods, with feed companies like Haida Group also highlighted [11] Key Agricultural Products Data Tracking - Corn: Current average price is 2378.15 CNY/ton, with a week-on-week increase of 0.15% [23] - Wheat: Current average price is 2457.51 CNY/ton, with a week-on-week decrease of 0.35% [26] - Soybeans: Current average price is 3927.89 CNY/ton, remaining stable [38] - Cotton: Current average price is 14480.00 CNY/ton, with a slight decrease of 0.14% [42] Feed and Vitamin Prices - The average price of pig feed is 2.71 CNY/kg, showing a week-on-week decrease of 0.73% [48] - Vitamin E is priced at 101.60 CNY/kg, with a decrease of 4.87% [48]

Fundraising Overview - The company has been approved by the China Securities Regulatory Commission to issue no more than 64,299,200 new shares, of which 31,420,573 shares were actually issued at a price confirmed on September 5, 2022 [1] - The funds raised are managed in accordance with regulatory guidelines and the company's internal management system, with specific accounts opened at various banks for the purpose of fund storage and management [1][2] Fund Usage and Account Status - The company has established special accounts for the raised funds at several banks, including China Construction Bank and Minsheng Bank, for projects such as the production of inactivated vaccines and the expansion of biological product workshops [2] - As of the announcement date, the status of the fundraising accounts is active, with specific projects linked to each account [2] Project Completion and Fund Reallocation - The company has concluded certain fundraising projects, specifically the "inactivated vaccine production project" and the "product quality inspection workshop project," and has decided to permanently allocate the remaining funds to working capital [3] - Following the completion of these projects, the corresponding fundraising accounts will be closed, and the related storage agreements will be terminated [3]

关于部分募集资金专户销户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于核准普莱柯生物工程股份有限公司非公 开发行股票的批复》（证监许可〔2022〕1251 号），普莱柯生物工程股份有限 公司（以下简称"公司"）获核准非公开发行不超过 64,299,200 股新股。公司实 际向发行对象非公开发行人民币普通股（A 股）股票 31,420,573 股，发行价格 28.58 元 / 股 ， 募 集 资 金 总 额 为 897,999,976.34 元 ， 扣 除 不 含 税 发 行 费 用 12,179,453.12 元，募集资金净额为人民币 885,820,523.22 元。上述资金于 2022 年 9 月 5 日全部到位，已经立信会计师事务所（特殊普通合伙）审验，并出具信 会师报字〔2022〕第 ZA15752 号《验资报告》。 二、募集资金存放与管理情况 为规范募集资金的管理和使用，保护投资者合法权益，公司依照《上市公司 监管指引第 2 号——上市公司募集资金管 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

Meeting Overview - The shareholders' meeting of Pulaike Biological Engineering Co., Ltd. was held on May 16, 2025, at the company's conference room in Luoyang, Henan Province [1] - The meeting was attended by shareholders representing 37.6494% of the total shares [1] - The meeting was conducted in accordance with the Company Law and the company's articles of association, with a combination of on-site and online voting [1] Voting Results - All proposed resolutions were approved by the shareholders [2][3] - The voting results for the A-shares showed a high approval rate, with the following key votes: - 128,331,003 votes in favor (99.6894%) for the first resolution [1] - 128,313,003 votes in favor (99.6755%) for the second resolution [1] - 128,310,603 votes in favor (99.6736%) for the third resolution [1] - 128,298,003 votes in favor (99.6638%) for the fourth resolution [1] - 128,314,403 votes in favor (99.6765%) for the fifth resolution [1] Major Proposals - The meeting included significant proposals such as: - The reappointment of the accounting firm for 2024 [4] - The use of idle funds for cash management [4] - The extension of certain fundraising projects [4] - The voting results for these proposals also reflected strong shareholder support, with approval rates exceeding 99% for most resolutions [2][3] Legal Compliance - The meeting was witnessed by lawyers from Beijing Deheng Law Firm, confirming that the procedures and results complied with relevant laws and regulations [5]

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：603566 证券简称：普莱柯 公告编号：2025-022 普莱柯生物工程股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路 15 号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 145 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 128,730,723 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 37.6494 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与 网络投票相结合的方式召开，北京德恒律师事务所律师出席了现场会议并见证。 ...

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的 法律意见 北京德恒律师事务所 DeHeng Law Offices 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 2024 年年度股东大会的 法律意见 德恒 01G20240892-01 号 本法律意见仅供普莱柯本次股东大会相关事项的合法性之目的使用. 不得用 作任何其他目的。 本所律师根据《公司法》《证券法》《上市公司股东会规则》等有关法律、法 规和规范性文件以及《公司章程》,按照律师行业公认的业务标准、道德规范和 勤勉尽责的精神,对普莱柯所提供的相关文件和有关事实进行了核查和验证,现 出具法律意见如下: 一、本次股东大会的召集、召开程序 2025 年 4 月 24 目, 公司第五届董事会第十八次会议审议通过《关于召开 2024 年年度股东大会的议案》。2025年 4 月 25 日，公司在指定信息披 ...